Get the Stockscreener App
50.84
1.36%
-0.50
Supernus Pharmaceuticals Inc stock is traded at $50.84, with a volume of 121.94K.
It is down -1.36% in the last 24 hours and down -1.40% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$51.34
Open:
$51.37
24h Volume:
121.94K
Relative Volume:
0.18
Market Cap:
$2.92B
Revenue:
$665.13M
Net Income/Loss:
$64.50M
P/E Ratio:
44.43
EPS:
1.1442
Net Cash Flow:
$185.87M
1W Performance:
+2.57%
1M Performance:
-1.40%
6M Performance:
+22.80%
1Y Performance:
+29.88%
1-Day Range:
$49.88
$51.59
1-Week Range:
$49.88
$51.99
52-Week Range:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
50.93 | 2.94B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.35 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.26 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.93 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.07 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Can Supernus Pharmaceuticals Inc. stock sustain institutional interestJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Is Supernus Pharmaceuticals (SUPN) Offering Value After Strong Multi Year Share Price Gains - Sahm
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Lupin launches epilepsy drug in US - ET Pharma
Lupin Launches Topiramate Extended-Release Capsules in the United States - The Malaysian Reserve
(SUPN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Strong results lifted Supernus Pharmaceuticals (SUPN) in Q3 - MSN
India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR - marketscreener.com
Patterns Watch: Should I trade or invest in Supernus Pharmaceuticals Inc2025 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
SupernusOutlook For 2026 Positive, Upholding Buy Rating (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat
Published on: 2026-01-31 06:25:45 - baoquankhu1.vn
Supernus Pharmaceuticals amends merger agreement to adjust milestone payments - Investing.com
Supernus Revises Merger Milestone Payment Obligations Agreement - TipRanks
Is Supernus Pharmaceuticals Inc. being accumulated by smart moneyJuly 2025 Patterns & Fast Exit and Entry Trade Guides - mfd.ru
Published on: 2026-01-28 12:01:32 - baoquankhu1.vn
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring a 24.76% Potential Upside - DirectorsTalk Interviews
Analysis Recap: Should you avoid Supernus Pharmaceuticals Inc. stock right nowWeekly Trade Analysis & Risk Managed Trade Strategies - baoquankhu1.vn
Price-Driven Insight from (SUPN) for Rule-Based Strategy - Stock Traders Daily
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years - simplywall.st
Loss Report: Is Supernus Pharmaceuticals Inc stock forming a triangle pattern2025 Buyback Activity & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Supernus Pharmaceuticals (SUPN) Stock Analysis: Exploring A 22.67% Potential Upside - DirectorsTalk Interviews
Chart Watch: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Investment Review: Should you avoid Supernus Pharmaceuticals Inc stock right now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
(SUPN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
How Supernus Pharmaceuticals Inc. stock performs after earningsJuly 2025 Pullbacks & Comprehensive Market Scan Insights - Улправда
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com - Investing.com UK
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Investment Recap: How Supernus Pharmaceuticals Inc stock compares to growth peersProduct Launch & Weekly High Momentum Picks - Bộ Nội Vụ
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Rice Hall James & Associates LLC Has $22.75 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells 20,000 Shares of Stock - MarketBeat
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Optimism flows from pot to psychedelics: Atai Beckley, Supernus stocks rise after analyst flags positive tailwinds from Trump’s marijuana order - MSN
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order - Stocktwits
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Option Exercise |
28.82 |
20,000 |
576,500 |
30,496 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Sale |
50.41 |
20,000 |
1,008,150 |
15,496 |
0.34%
8.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):